Digestive and Liver Disease
Volume 42, Issue 5 , Pages 331-340, May 2010

Prevention and treatment of nonalcoholic fatty liver disease

  • Giovanni Targher

      Affiliations

    • Sezione di Endocrinologia, Dipartimento di Scienze Biomediche e Chirurgiche, Università di Verona, Verona, Italy
  • ,
  • Alessandro Bellis

      Affiliations

    • Dipartimento di Medicina Clinica, Scienze Cardiovascolari ed Immunologiche, Università “Federico II”, Napoli, Italy
  • ,
  • Paolo Fornengo

      Affiliations

    • Dipartimento di Medicina Interna, Università di Torino, Torino, Italy
  • ,
  • Francesca Ciaravella

      Affiliations

    • Sezione di Malattie del Metabolismo e Dietetica Clinica, Università “Alma Mater Studiorum”, Bologna, Italy
  • ,
  • Isabella Pichiri

      Affiliations

    • Sezione di Endocrinologia, Dipartimento di Scienze Biomediche e Chirurgiche, Università di Verona, Verona, Italy
  • ,
  • Paolo Cavallo Perin

      Affiliations

    • Dipartimento di Medicina Interna, Università di Torino, Torino, Italy
  • ,
  • Bruno Trimarco

      Affiliations

    • Dipartimento di Medicina Clinica, Scienze Cardiovascolari ed Immunologiche, Università “Federico II”, Napoli, Italy
  • ,
  • Giulio Marchesini

      Affiliations

    • Sezione di Malattie del Metabolismo e Dietetica Clinica, Università “Alma Mater Studiorum”, Bologna, Italy
    • Corresponding Author InformationCorresponding author at: Malattie del Metabolismo e Dietetica Clinica, Università “Alma Mater Studiorum”, Azienda Ospedaliera di Bologna, Policlinico S. Orsola-Malpighi, Via Massarenti, 9, I-40138 Bologna, Italy.

Received 25 January 2010; accepted 1 February 2010. published online 08 March 2010.

Abstract 

A better knowledge of the biochemical mechanisms implicated in the development and progression of nonalcoholic fatty liver disease, linking fatty liver to insulin resistance and the metabolic syndrome, has shifted the goal of treatment from a mere clearing of fat from the liver to a systematic treatment of metabolic risk factors for fatty liver. Any attempt to modify the “unhealthy” habits responsible for fatty liver requires an integrated approach, based on the cognitive theory of behaviour by a multidisciplinary team including physicians, psychologists, dieticians and physical exercise experts, and recent data demonstrate that this is feasible and effective. Whenever this goal is not attained, a treatment based on insulin-sensitizers remains the best option, to simultaneously tackle all metabolic alterations of the metabolic syndrome. However, in individual patients, both raised blood pressure and dyslipidemia need to be controlled, in order to reduce cardiovascular risk. In these areas, any attempt should be made to use of drugs less likely to induce a deterioration of glucose control. It remains to be determined whether these treatments are able to modify the natural history of nonalcoholic fatty liver disease in the long term.

Keywords: Cognitive-behavioural therapy, Insulin resistance, Metabolic syndrome, Pharmacological treatment

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Based on lectures presented at the Single Topic Conference of the Italian Association for the Study of the Liver “The Central Role of the Liver in the Metabolic Syndrome”, Naples, 12–13 June 2008.

PII: S1590-8658(10)00052-6

doi:10.1016/j.dld.2010.02.004

Digestive and Liver Disease
Volume 42, Issue 5 , Pages 331-340, May 2010